Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov:175:246-253.
doi: 10.1016/j.ejca.2022.08.019. Epub 2022 Sep 24.

Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population

Samuel Vic  1 , Jean Lemoine  2 , Philippe Armand  3 , François Lemonnier  4 , Roch Houot  5
Affiliations
Review

Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population

Samuel Vic et al. Eur J Cancer. 2022 Nov.

Abstract

Autologous stem cell transplantation (ASCT) and chimeric antigen receptor (CAR) T-cells are two therapeutic options for relapsed/refractory diffuse large B-cell lymphoma. Both are intensive and potentially curative therapies but differ in their efficacy and toxicity. ASCT may be offered to 'fit' patients (i.e. usually young with limited comorbidities) with chemosensitive disease. On the other hand, real world studies have shown that CAR T-cells may be safely administered to less fit and older patients. Thus, there is a potentially significant population of patients who may be offered CAR T-cell therapy despite not being eligible for ASCT. As the relative role of ASCT and CAR T-cells evolves, recognising and defining this population may be increasingly relevant. Here, we review criteria which may help identify this 'ASCT-ineligible but CAR T-cells eligible' population of patients.

Keywords: Lymphoma; autologous stem cell transplantation; chimeric antigen receptor T-cells.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: François Lemonnier: Grants (institutions): INCA, ARC, Force Hémato, Consulting fees: Miltenyi, Kiowa, Payment or honoraria: Miltenyi, Support for attending meetings and/or travel: Gilead, Abbvie. Philippe Armand: Consultancy: Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome, Regeneron, Epizyme, Astra Zeneca, Genentech, Xencor, Research funding: Kite, Research funding (institutional): Merck, BMS, Affimed, Adaptive, Tensha, Otsuka, Sigma Tau, Genentech/Roche, IGM, Honoraria: Merck, BMS. Roch Houot: Consulting fees: Gilead, Kite, Bristol-Myers Squibb, Novartis. Payment or honoraria: Bristol-Myers Squibb, MSD, Gilead, Kite, Roche, Novartis, Janssen, Takeda and Celgene. Jean Lemoine: None declared. Samuel Vic: None declared.

MeSH terms

Substances

LinkOut - more resources